Neluxicapone

Neluxicapone
Clinical data
Drug classCatechol O-methyltransferase inhibitor
Identifiers
  • 4,5-dihydroxy-2-[(4-methylphenyl)methyl]benzene-1,3-dicarbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H12N2O2
Molar mass264.284 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)CC2=C(C(=C(C=C2C#N)O)O)C#N
  • InChI=1S/C16H12N2O2/c1-10-2-4-11(5-3-10)6-13-12(8-17)7-15(19)16(20)14(13)9-18/h2-5,7,19-20H,6H2,1H3
  • Key:GILLLKMLIBNDKV-UHFFFAOYSA-N

Neluxicapone (INNTooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024. The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone. COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease. Neluxicapone was first described in the literature by 2018. Its INNTooltip International Nonproprietary Name was designated by the World Health Organization (WHO) in 2019.